ScripBristol Myers Squibb’s new executive vice president, chief medical officer and head of development Christian Massacesi will have the task of bringing new growth drivers to market amid loss-of-exclusiv
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis, Matchpoint Will Seek Out Oral
ScripAstraZeneca intends to bring a self-administered complement C5 inhibitor to market for generalized myasthenia gravis (gMG) now that gefurulimab has delivered positive Phase III results. The product co
ScripRoche’s recent Phase III failure for its anti-ST2 monoclonal antibody, astegolimab, in chronic obstructive pulmonary disease (COPD) is a blow not just for the firm but also for the fledgling drug clas